Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?†‡

Kathleen N. Moore MD; Chunqiao Tian PhD; D. Scott McMeekin MD; J. Tate Thigpen MD; Marcus E. Randall MD; Holly H. Gallion MD

首页> 外文期刊>Cancer >Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?†‡

【24h】

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?†‡

机译：原发性化疗后无进展间隔是否可以预测晚期和复发性子宫内膜癌的挽救性化疗后的生存率？† ‡

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Precision Therapeutics, Pittsburgh, Pennsylvania

机译：宾夕法尼亚州匹兹堡的精密治疗学

著录项

来源
《Cancer》 |2010年第23期|p.5407-5414|共8页
作者
Kathleen N. Moore MD; Chunqiao Tian PhD; D. Scott McMeekin MD; J. Tate Thigpen MD; Marcus E. Randall MD; Holly H. Gallion MD;
展开▼
作者单位

Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma;

Gynecologic Oncology Group Statistical Center, Buffalo, New York;

Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi;

Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky;

Precision Therapeutics, Pittsburgh, Pennsylvania;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
endometrial cancer; chemotherapy; Gynecologic Oncology Group; ancillary data analysis; salvage chemotherapy;

机译：子宫内膜癌;化学疗法;妇科肿瘤学组;辅助数据分析;挽救性化疗;

相似文献

外文文献
中文文献
专利

1. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. [J] . Moore KN, Tian C, McMeekin DS, Cancer: A Journal of the American Cancer Society . 2010,第23期

机译：原发性化疗后的无进展间隔是否可预测晚期和复发性子宫内膜癌的挽救性化疗后的存活率？：妇科肿瘤学组辅助数据分析。
2. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. [J] . Moore KN, Tian C, McMeekin DS, Cancer: A Journal of the American Cancer Society . 2010,第23期

机译：原发性化疗后的无进展间隔是否可预测晚期和复发性子宫内膜癌的挽救性化疗后的生存率？：妇科肿瘤学小组的辅助数据分析。
3. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer†‡§¶ [J] . John H. Farley MD, Chunqiao Tian MS, G. Scott Rose MD, Cancer . 2010,第2期

机译：患有晚期和复发性子宫内膜癌的黑人和白人女性的化疗强度和毒性† ‡ § ¶
4. Computer extracted features related to the spatialarrangement of tumor-infiltrating lymphocytes predict overall survival in epithelial ovarian cancer receiving adjuvant chemotherapy [C] . Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Conference on Medical Imaging: Digital Pathology . 2020

机译：计算机提取与空间相关的功能肿瘤浸润淋巴细胞的安排预测上皮性卵巢癌接受佐剂化疗的整体存活
5. Predicting chemotherapy resistance in breast cancer patients using radiofluorinated analogues of chemotherapy agents in conjunction with positron emission tomography. [D] . Kesner, Amanda Lovell. 2003

机译：结合使用化疗剂的放射性氟化类似物和正电子发射断层扫描术，可以预测乳腺癌患者的化疗耐药性。
6. PIPAC-OV3: A multicenter open-label randomized two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian fallopian tube or primary peritoneal cancer [O] . Naoual Bakrin, Clemens Tempfer, Giovanni Scambia, 2018

机译：PIPAC-OV3：一项多中心开放标签随机三臂III期临床试验对加压铂-腹膜内气雾剂化疗（PIPAC）与单独化疗的铂-铂类患者对顺铂和阿霉素的无进展生存期有影响耐药的复发性上皮性卵巢癌输卵管癌或原发性腹膜癌
7. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? [O] . Kathleen N. Moore, Chunqiao Tian, D. Scott McMeekin, 2010

机译：初级化疗后的进展间隔是否在先进和复发子宫内膜癌中抢救后预测存活？

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?†‡

摘要

著录项

相似文献

相关主题

期刊订阅